The PE Ratio as of November 2024 (TTM) for Gossamer Bio, Inc. (GOSS) is -2.78

According to Gossamer Bio, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -2.78. This represents a change of 217.63% compared to the average of -0.88 of the last 4 quarters.

Gossamer Bio, Inc. (GOSS) Historical PE Ratio (quarterly & annually)

How has GOSS PE Ratio performed in the past?

The mean historical PE Ratio of Gossamer Bio, Inc. over the last ten years is -681.58. The current -2.78 PE Ratio has changed -59.21% with respect to the historical average. Over the past ten years (40 quarters), GOSS's PE Ratio was at its highest in in the June 2024 quarter at 1.09. The PE Ratio was at its lowest in in the March 2017 quarter at -2490.13.

Gossamer Bio, Inc. (GOSS) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Gossamer Bio, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Gossamer Bio, Inc. (GOSS) Average PE Ratio

How has GOSS PE Ratio performed in the past?

The current PE Ratio of Gossamer Bio, Inc. (GOSS) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

Gossamer Bio, Inc. (GOSS) PE Ratio vs. Peers

How is GOSS’s PE Ratio compared to its peers?

Gossamer Bio, Inc.’s PE Ratio is less than Biomea Fusion, Inc. (-1.62), greater than Stoke Therapeutics, Inc. (-6.11), greater than Akero Therapeutics, Inc. (-9.58), less than Homology Medicines, Inc. (-0.01), greater than Replimune Group, Inc. (-5.51), greater than Nuvectis Pharma, Inc. (-4.54), less than Lyra Therapeutics, Inc. (-0.13), less than Kronos Bio, Inc. (-0.64), less than Passage Bio, Inc. (-0.45), less than Black Diamond Therapeutics, Inc. (-1.96), less than TCR2 Therapeutics Inc. (-0.38), greater than Harpoon Therapeutics, Inc. (-122.60), less than Alector, Inc. (-2.40), greater than Terns Pharmaceuticals, Inc. (-5.12), less than Amylyx Pharmaceuticals, Inc. (-1.38), less than Acumen Pharmaceuticals, Inc. (-1.74), less than Inozyme Pharma, Inc. (-1.84), greater than X4 Pharmaceuticals, Inc. (-4.05), less than Atreca, Inc. (-0.06), greater than 4D Molecular Therapeutics, Inc. (-3.02),

Build a custom stock screener for Gossamer Bio, Inc. (GOSS) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Gossamer Bio, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Gossamer Bio, Inc. (GOSS) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Gossamer Bio, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.